Imatinib Mesylate and Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes
necessary for tumor cell growth. Drugs used in chemotherapy use different ways to stop tumor
cells from dividing so they stop growing or die. Combining imatinib mesylate with
chemotherapy may kill more tumor cells.
PURPOSE: Phase I trial to study the effectiveness of combining imatinib mesylate with
irinotecan and cisplatin in treating patients who have extensive-stage small cell lung cancer